Current News

Contact | Print version | Send article | RSS feed

Ablynx and Boehringer Ingelheim sign $265 million research and licensing agreement to develop new Alzheimer's treatments

10 Jan 2007 - Boehringer Ingelheim and Ablynx have jointly announced an exclusive worldwide collaboration and licence agreement worth almost $265 million to discover and develop new therapies for Alzheimer's disease using Ablynx' NanobodiesŪ, a novel class of therapeutic proteins. In addition Boehringer Ingelheim will commence a joint research programme including Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture and commercialisation of any products resulting from the collaboration. The deal includes an upfront fee, development and commercial milestones. Ablynx will also receive undisclosed royalties based on net sales.
 
According to the company, Ablynx' NanobodiesŪ could be particularly important in developing new Alzheimer's disease treatments, as researchers believe they could solve the problems faced by other drugs or conventional treatments. Due to their special characteristics, NanobodiesŪ may cross the blood-brain barrier more readily than conventional antibodies.